C12N 2760/20232
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/20232 (Use of virus as therapeutic agent, other than vaccine) appears on 64 US grants and 134 published applications in this corpus.
Search patents in C12N- Granted patents
- 64
- Published applications
- 134
- Assignees
- 53
- Inventors
- 170
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 5 |
| 2011 | 1 | 4 |
| 2012 | 2 | 4 |
| 2013 | 2 | 1 |
| 2014 | 0 | 6 |
| 2015 | 1 | 5 |
| 2016 | 1 | 4 |
| 2017 | 3 | 4 |
| 2018 | 5 | 9 |
| 2019 | 5 | 11 |
| 2020 | 10 | 7 |
| 2021 | 3 | 13 |
| 2022 | 1 | 9 |
| 2023 | 6 | 7 |
| 2024 | 5 | 20 |
| 2025 | 13 | 13 |
| 2026 | 5 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- Compositions and methods of use of oncolytic virus like vesicles17 Mar 2026US 12,577,585 B2Carogen Corporation
- VSV chimeric vectors13 Jan 2026US 12,522,844 B2Boehringer Ingelheim International GmbH
- Recombinant oncolytic virus and use thereof16 Jul 2026US 2026/0199415 A1Joint Biosciences (Sh) Ltd.
- Macrophage depletion and vesicular stomatitis virus for treatment of cancer7 May 2026US 2026/0125459 A1Boehringer Ingelheim International GmbH
- Recombinant rhabdovirus encoding for a gasdermin30 Apr 2026US 2026/0117200 A1Boehringer Ingelheim International GmbH
- Mutated Glycoprotein of Vesicular Stomatitis Virus19 Mar 2026US 2026/0078150 A1Centre National de la Recherche Scientifique (CNRS)
- Method for treating tumors using combination of oncolytic virus vaccine and immune cells15 Jan 2026US 2026/0014238 A1Joint Biosciences (Sh) Ltd.
Most cited
By later US patents
- Mutant vesicular stomatitis viruses and uses thereof37US 7,731,974 B2Ottawa Hospital Research Institute · 2010
- Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof10US 10,232,003 B2BeneVir Biopharm, Inc. · 2019
- Mutated glycoprotein of vesicular stomatitis virus10US 12,030,915 B2Centre National de la Recherche Scientifique (CNRS) · 2024
- Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers7US 8,012,489 B22011
- Compositions and methods for enhancing virus efficacy5US 8,940,291 B2Ottawa Hospital Research Institute · 2015